Pseudouridimycin competes with incoming nucleotides to inhibit bacterial RNA polymerase, effectively blocking growth of a broad range of pathogens. Maffioli et al., 2017, Cell 169, 1240 
SUMMARY
Drug-resistant bacterial pathogens pose an urgent public-health crisis. Here, we report the discovery, from microbial-extract screening, of a nucleosideanalog inhibitor that inhibits bacterial RNA polymerase (RNAP) and exhibits antibacterial activity against drug-resistant bacterial pathogens: pseudouridimycin (PUM). PUM is a natural product comprising a formamidinylated, N-hydroxylated Gly-Gln dipeptide conjugated to 6 0 -amino-pseudouridine. PUM potently and selectively inhibits bacterial RNAP in vitro, inhibits bacterial growth in culture, and clears infection in a mouse model of Streptococcus pyogenes peritonitis. PUM inhibits RNAP through a binding site on RNAP (the NTP addition site) and mechanism (competition with UTP for occupancy of the NTP addition site) that differ from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif). PUM exhibits additive antibacterial activity when co-administered with Rif, exhibits no cross-resistance with Rif, and exhibits a spontaneous resistance rate an order-of-magnitude lower than that of Rif. PUM is a highly promising lead for antibacterial therapy.
INTRODUCTION
There is an urgent need for new antibacterial drugs effective against bacterial pathogens resistant to current drugs (reviewed in Marston et al., 2016; Brown and Wright, 2016) .
Bacterial RNA polymerase (RNAP) is a proven target for broadspectrum antibacterial therapy (reviewed in Mariani and Maffioli, 2009; Ho et al., 2009; Aristoff et al., 2010; Srivastava et al., 2011) . The suitability of bacterial RNAP as a target for broad-spectrum antibacterial therapy follows from the fact that bacterial RNAP is an essential enzyme (permitting efficacy), the fact that bacterial RNAP subunit sequences are highly conserved (providing a basis for broad-spectrum activity), and the fact that bacterial RNAP-subunit sequences are not highly conserved in eukaryotic RNAP I, RNAP II, and RNAP III (providing a basis for therapeutic selectivity).
RNAP is the target of two classes of antibacterial drugs currently in clinical use: (1) rifamycins (rifampin [Rif] , rifapentine, rifabutin, and rifamixin), which function by binding to a site adjacent to the RNAP active center and sterically inhibiting extension of short RNA products (Campbell et al., 2001; Feklistov et al., 2008; Lin et al., 2017) ; and (2) lipiarmycins (fidaxomicin), which function by binding to a site distant from the RNAP active center and allosterically inhibiting initial RNAP-DNA interaction (Ebright, 2005; Srivastava et al., 2011) . Bacterial RNAP also is the target of a class of antibacterial agents currently in preclinical development: myxopyronins, which function by binding to a site distant from the RNAP active center and allosterically inhibiting opening of, and loading of DNA into, the RNAP active-center cleft (Mukhopadhyay et al., 2008; Belogurov et al., 2009; Srivastava et al., 2011) . Rifamycins, lipiarmycins, and myxopyronins are subject to spontaneous resistance emergence (Mariani and Maffioli, 2009; Ho et al., 2009; Aristoff et al., 2010; Srivastava et al., 2011 Srivastava et al., , 2012 . Resistance to rifamycins, lipiarmycins, and myxopyronins arises from mutations that result in substitution of the respective binding sites on RNAP for the compounds, preventing binding of the compounds.
Nucleoside-analog inhibitors (NAIs) that selectively inhibit viral nucleotide polymerases have had transformative impact on treatment of HIV (e.g., AZT, DDI, DDC, 3TC, d4T, and tenofovir; reviewed in Cihlar and Ray, 2010) and HCV (e.g., sofosbuvir; reviewed in Summers et al., 2014) . NAIs that selectively inhibit bacterial RNAP potentially could have an analogous impact on the treatment of bacterial infections, particularly because functional constraints on substitution of RNAP nucleoside-triphosphate (NTP) binding sites could limit substitutions that confer resistance (Summers et al., 2014; Zhang et al., 2014) .
Here, we report the discovery, from microbial-extract screening, of the first NAI that selectively inhibits bacterial RNAP.
RESULTS AND DISCUSSION

Identification of PUM
We screened a library of 3,000 Actinobacterial (Landwehr et al., 2016) and fungal culture extracts for the ability to inhibit RNAP, and we identified two extracts that inhibited bacterial RNAP (E. coli RNAP) but did not inhibit a structurally unrelated bacteriophage RNAP (SP6 RNAP) and did not contain a previously characterized inhibitor of bacterial RNAP (see Method Details). Fractionation of the two extracts by reversed-phase chromatography and structure elucidation of active components by mass spectrometry and multidimensional NMR spectrometry revealed that the extracts contained the same active component: pseudouridimycin (PUM; Figures 1A and S1 ).
RNAP-Inhibitory and Antibacterial Activity of PUM PUM selectively inhibits bacterial RNAP (IC 50 = 0.1 mM; selectivity >4-to >500-fold; Figures 1B and S2; Table S1), selectively Azi, azithromycin; Cip, ciprofloxacin; Ctr, ceftriaxone; Dap, daptomycin; Ery, erythromycin; Chl, chloramphenicol; Cli, clindamycin; Gen, gentamicin; Lin, linezolid; Met, methicillin; Mup, mupirocin; Pen, penicillin; Ox, oxacillin; Rif, rifampin; Tec, teicoplanin; Tet, tetracycline; Tri, trimethoprim; Van, vancomycin. (D) Antibacterial activity of PUM in vivo. (E) Absence of cross-resistance between PUM and Rif (data for S. pyogenes Rif-resistant mutants; residues numbered as in S. pyogenes and, in parentheses, E. coli).
(F) Additive antibacterial activity of PUM and Rif. See Tables S1 and S2 and Figures S1 and S2. inhibits bacterial growth (IC 50 = 2-16 mM; selectivity >6-to >60-fold; Figure 1C ), and clears infection in vivo in a mouse Streptococcus pyogenes peritonitis model (ED 50 = 9 mg/kg; Figure 1C ; Table S2 ). PUM exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria and against both drug-sensitive and drug-resistant bacterial strains, including rifamycin-, b-lactam-, fluoroquinolone-, macrolide-, tetracycline-, aminoglycoside-, lincosamide-, chloramphenicol-, oxazolidinone-, trimethoprim-, glycopeptide-, lipopeptide-, mupirocin-, and multi-drug-resistant strains ( Figure 1C) . PUM exhibits no cross-resistance with the classic RNAP inhibitor Rif ( Figures 1B, 1C , and 1E), exhibits additive antibacterial activity when co-administered with Rif ( Figure 1F ), and exhibits spontaneous resistance rates an order-of-magnitude lower than those of Rif (Figure 2A ), suggesting that PUM inhibits RNAP through a binding site and mechanism different from those of Rif.
Target of Transcription Inhibition by PUM
Gene sequencing indicates that PUM-resistant mutants contain mutations in the rpoB gene (encodes RNAP b subunit) or the rpoC gene (encodes RNAP b 0 subunit), confirming that RNAP is the functional cellular target of PUM (Figures 2B, S3A, and S3B) . In the Gram-positive bacterium S. pyogenes, substitutions conferring R4x PUM resistance are obtained at four sites: b residues 565, 681, and 684 and b 0 residue 786 (numbered as in E. coli RNAP; Figure 2B ). In the Gram-negative bacterium E. coli, substitutions conferring PUM resistance are obtained at two sites: b residues 565 and 681 (Figures S3A and S3B) . The number of sites of substitutions conferring PUM resistance is an order-of-magnitude lower than the number of sites of substitutions conferring Rif-resistance (2-4 versus 25; Jin and Gross, 1988; Garibyan et al., 2003) , consistent with, and accounting for, the observation that spontaneous resistance rates for PUM are an order-of-magnitude lower than those for Rif ( Figure 2A ).
Mapping the sites of substitutions conferring PUM resistance onto the three-dimensional structure of bacterial RNAP shows that the sites form a single discrete cluster (''PUM target''; Figures 2C and S3D) . The PUM target is located within the RNAP activecenter region and overlaps the RNAP active-center NTP addition site (''A site'' also referred to as ''i+1 site' '; Figures 2C and S3D) , suggesting that PUM inhibits RNAP by interfering with function of the NTP addition site. The PUM target is different from, and does not overlap, the Rif target (Figures 2D and S3E; Jin and Gross, 1988; Campbell et al., 2001; Garibyan et al., 2003) , consistent with, and accounting for, the observation that PUM does not share cross-resistance with Rif ( Figures 1B, 1C , 1E, 2E, S3F, and S3G) and the observation that PUM and Rif exhibit additive antibacterial activity ( Figure 1F ). The PUM target also is different from, and does not overlap, the targets of the RNAP inhibitors lipiarmycin (Lpm) (Ebright, 2005; Srivastava et al., 2011) , myxopyronin (Myx) (Mukhopadhyay et al., 2008; Belogurov et al., 2009; Srivastava et al., 2011) , streptolydigin (Stl) (Tuske et al., 2005; Temiakov et al., 2005) , CBR703 (CBR) (Feng et al., 2015; Bae et al., 2015) , and salinamide (Sal) (Degen et al., 2014; Figures 2D and S3E) , and, correspondingly, PUM does not exhibit cross-resistance with Lpm, Myx, Stl, CBR703, and Sal (Figures 2E, S3F, S3H, and S3I) . The PUM target partly overlaps the target for the RNAP inhibitor GE23077 (GE) ( Figure S3M ; Zhang et al., 2014) , and, correspondingly, PUM exhibits partial cross-resistance with GE ( Figure S3N ).
Biochemical Basis of Transcription Inhibition by PUM
The observation that PUM is an NAI that has the same WatsonCrick base-pairing specificity as UTP ( Figure 1A ) and the observation that the PUM target overlaps the RNAP NTP addition site (Figures 2B and S3A) suggest the hypothesis that PUM functions as an NAI that competes with UTP for occupancy of the RNAP NTP addition site. Five biochemical results support this hypothesis. First, PUM inhibits transcription by inhibiting nucleotide addition ( Figure S4 ). Second, high concentrations of UTP-but not high concentrations of GTP, ATP, or CTP-overcome transcription inhibition by PUM ( Figure 3A) . Third, PUM inhibits transcription only on templates that direct incorporation of U ( Figure 3B ). Fourth, in single-nucleotideaddition transcription reactions, PUM inhibits incorporation of U, but not G, A, or C ( Figure 3C ). Fifth, in multiple-nucleotide-addition transcription reactions, PUM inhibits incorporation of U, but not G, A, or C ( Figure 3D ). The results in Figures  3C and 3D further establish that transcription inhibition by PUM not only requires a template position that directs incorporation of U but also strongly prefers a preceding template position that directs incorporation of G, A, or U. We conclude that PUM functions as an NAI that competes with UTP at positions (C) Single-nucleotide-addition reactions showing that inhibition by PUM requires template positions directing incorporation of U (row 1) and prefers preceding template positions directing incorporation of G, A, or U (columns 1-3) (E. coli RNAP; 2.5 mM NTPs). UTP, GTP, ATP, or CTP (left), incoming NTP; G, A, U, or C (top), nucleotide at RNA 3 0 end; 9 nt RNA (right), precursor for single-nucleotide addition; 10 nt RNA (right), product of single-nucleotide addition; % (right), percent yield of 10 nt RNA in presence of PUM versus in absence of PUM.
(D) Multiple-nucleotide-addition reactions showing that inhibition by PUM requires template positions directing incorporation of U (red GU, AU, or UU, and pink CU) and prefers preceding template positions directing incorporation of G, A, or U (red GU, AU, or UU) (E. coli RNAP; 10 mM NTPs).See Figure S4 .
that direct incorporation of U preceded by positions that direct incorporation of G, A, or U.
Structural Basis of Transcription Inhibition by PUM
To define the structural basis of transcription inhibition by PUM, we determined a crystal structure of a transcription initiation complex containing PUM (RPo-GpA-PUM; Figure 4A ) and, for comparison, a crystal structure of a corresponding transcription initiation complex containing CMPcPP, a non-hydrolysable NTP analog shown previously to be able to stably occupy the RNAP NTP addition site (Zhang et al., 2014) (RPo-GpA-CMPcPP; Figure 4B) . The results establish that PUM is an NAI that competes for occupancy of the RNAP NTP addition site (Figure 4 ). PUM binds to the NTP addition site ( Figure 4A ). The PUM base makes
Watson-Crick hydrogen bonds with a DNA template-strand A in a manner equivalent to an NTP base; the PUM sugar moiety makes interactions with the NTP addition site in a manner nearly equivalent to an NTP sugar; the PUM glutamine moiety makes interactions that mimic interactions made by an NTP triphosphate; and the PUM N-hydroxy and guanidinyl moieties interact with the RNA nucleotide base-paired to the preceding template position (RNA 3 0 nucleotide), with the N-hydroxy donating a hydrogen bond to the 3 0 OH of the RNA 3 0 nucleotide and the guanidinyl moiety donating one hydrogen bond to the 5 0 phosphate of the RNA 3 0 nucleotide and another to the base of the RNA 3 0 nucleotide ( Figure 4A ).
The structure of the PUM-inhibited complex accounts for the observed specificity of inhibition for template positions that Figure S5 . direct incorporation of U preceded by template positions that direct incorporation of G, A, or U. The Watson-Crick base pair by the PUM base moiety with the DNA template strand provides absolute specificity for a position directing incorporation of U ( Figure 4A ). The hydrogen bond donated by the PUM guanidinyl moiety with the base of the RNA 3 0 nucleotide confers specificity for a preceding position directing incorporation of G, A, or U (each of which contains a hydrogen-bond acceptor at the appropriate position; Figure 4A ).
The structure also explains the selectivity of transcription inhibition by PUM. All RNAP residues contacted by PUM are highly conserved across Gram-positive and Gram-negative bacterial RNAP ( Figure S5 ), accounting for the inhibition of both Grampositive and Gram-negative bacterial RNAP. In contrast, four RNAP residues important for PUM are not conserved in human RNAP I, II, and III (b residues 677, 681, and 684 and b 0 residue 932; Figure S5 ), accounting for selectivity for bacterial RNAP over human RNAP I, II, and III. The structure also explains the small size of the PUM-resistance spectrum (four residues in S. pyogenes RNAP; two residues in E. coli RNAP; Figures 2B, S3A, and S3B). PUM makes direct contacts with RNAP residues at which PUMresistant substitutions are obtained (Figure S5) . However, PUM also makes direct contacts with ten other RNAP residues that comprise functionally critical residues of the RNAP active center that cannot be readily substituted without compromising RNAP activity (Sagitov et al., 1993; Svetlov et al., 2004; Sosunov et al., 2005; Jovanovic et al., 2011; Yuzenkova et al., 2012; Zhang et al., 2014) and thus that cannot be readily substituted to yield viable, fully fit, resistant mutants ( Figure 4A ; Zhang et al., 2014) . We infer that PUM interacts with a ''privileged target'' for which most residues (10-12 of 14 residues) have functional constraints that limit substitution to yield viable resistant mutants. Similar results have been reported for the RNAP inhibitor GE, a non-nucleoside-analog inhibitor that binds to the RNAP active center (Zhang et al., 2014) and that exhibits a small target-based resistance spectrum (Zhang et al., 2014) (but that, unlike PUM, exhibits high non-target-based resistance, presumably at the level of uptake or efflux, precluding development as an antibacterial drug).
The structure enables structure-based design of PUM analogs with increased potency and increased selectivity. Initial leadoptimization efforts corroborate the importance of the PUM N-hydroxy, glutamine, and guanidinyl moieties and demonstrate that the PUM glutamine C(O)NH 2 can be replaced by C(O)NHR while retaining RNAP inhibitory and antibacterial activity ( Figure 5 ).
Prospect
Our results provide a new class of antibiotic with activity against Gram-positive and Gram-negative bacteria in vitro and in vivo, no cross-resistance with current antibacterial drugs, and low rates of resistance emergence. Our discovery of this class of antibiotic from conventional microbial extract screening indicates that, contrary to widespread belief (Marston et al., 2016) Sosunov, V., Zorov, S., Sosunova, E., Nikolaev, A., Zakeyeva, I., Bass, I., Goldfarb, A., Nikiforov, V., Severinov, K., and Mustaev, A. (2005) . Table S4 this paper N/A bacteriophage T4 N25 promoter DNA fragment, see Table S4 Revyakin et al., 2006 N25-100-tR2
Cy5-labeled lacUV5 promoter DNA fragment, see Table S4 Mukhopadhyay et al., 2008 Cy5-lacUV5-[-40; +15] nontemplate-strand, template-strand, and RNA oligos for transcription-elongation-complex scaffolds, see Table S5 IDT N/A Table S4 IDT N/A S. pyogenes rpoC primers, see Table S4 IDT 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by Lead Contact, Richard H. Ebright (ebright@waksman.rutgers.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Female ICR mice were obtained from Harlan Laboratories, Italy. All mice weighed 23-25 g when tested. Mice were adapted to standardized environmental conditions (temperature = 23±2 C; humidity = 55±10%) for one week prior to infection. Procedures were performed in accordance with the institution's guidelines for the humane handling, care, and treatment of research animals.
Cell line and cell culture HeLa cells were grown to 70%-80% confluence in DMEM, high-glucose, 2 mM L-glutamine medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were maintained at 37 C in a 5% CO 2 incubator.
METHOD DETAILS
E. coli RNAP core enzyme For experiments in Figure 3C , E. coli RNAP core enzyme was prepared from E. coli strain BL21(DE3) (Invitrogen/ThermoFisher) transformed with plasmids pEcABC-H6 (Hudson et al., 2009 ) and pCDFu (Vrentas et al., 2005) , using culture and induction procedures as in Hudson et al., 2009 , and using polyethylenimine precipitation, ammonium-sulfate precipitation, immobilized-metal-ion affinity chromatography on Ni-NTA agarose (QIAGEN), and anion-exchange chromatography on Mono Q (GE Healthcare), as in Mukhopadhyay et al., 2003 . For experiments assessing promoter-independent transcription in Table S1 , E. coli RNAP core enzyme was prepared from E. coli strain XE54 (Tang et al., 1994) transformed with plasmid pRL706 (Severinov et al., 1997) , using culture and induction procedures, polyethylenimine precipitation, ammonium-sulfate precipitation, immobilized-metal-ion affinity chromatography on Ni-NTA agarose (QIAGEN), and anion-exchange chromatography on Mono Q (GE Healthcare), as in Niu et al., 1996.
E. coli RNAP s 70 holoenzyme
For experiments in Figure 1B, For experiments in Figure 3D , E. coli RNAP s 70 holoenzyme was prepared from E. coli strain XE54 (Tang et al., 1994) transformed with plasmid pREII-NHa (Niu et al., 1996) , using culture and induction procedures, polyethylenimine precipitation, ammonium-sulfate precipitation, immobilized-metal-ion affinity chromatography on Ni-NTA agarose (QIAGEN), and anion-exchange chromatography on Mono Q (GE Healthcare), as in Degen et al., 2014 .
S. aureus RNAP s A holoenzyme
S. aureus RNAP core enzyme was prepared from E. coli strain BL21(DE3) (Invitrogen/ThermoFisher) transformed with plasmids pCOLADuet-Sau-BC, pACYCDuet-Sau-H10-A, and pCDFDuet-Sau-Z, using polyethylenimine precipitation, ammonium-sulfate precipitation, immobilized-metal-ion affinity chromatography on Ni-NTA agarose (QIAGEN), and cation-exchange chromatography on HiPrep Heparin (GE Healthcare); S. aureus s A was prepared from E. coli strain BL21(DE3) transformed with pET21a-Sau-H6-sigA, using immobilized-metal-ion affinity chromatography on Ni-NTA agarose (QIAGEN T. thermophilus RNAP s A holoenzyme T. thermophilus RNAP core enzyme was prepared from T. thermophilus strain H8 (DSM 579; DSMZ), using polyethylenimine precipitation, ammonium-sulfate precipitation, cation-exchange chromatography on SP Sepharose FF (GE Healthcare), anion-exchange chromatography on Mono Q (GE Healthcare), and cation-exchange chromatography on Mono S (GE Healthcare); T. thermophilus s A was prepared from E. coli strain BL21(DE3) transformed with pET28a-Tt-s A , using immobilized-metal-ion affinity chromatography on Ni-NTA agarose (QIAGEN) and anion-exchange chromatography on Mono Q (GE Healthcare); T. thermophilus RNAP core enzyme and T. thermophilus s A were combined to yield T. thermophilus RNAP s A holoenzyme; and T. thermophilus RNAP s A holoenzyme was further purified using size-exclusion chromatography on Superdex 200 (GE Healthcare), as in Zhang et al., 2014.
Microbial extract screening
A sub-library of $3,000 microbial extracts (prepared as in Donadio et al., 2009 ) with growth-inhibitory activity against S. aureus ATCC 6538 was screened for the ability to inhibit E. coli RNAP and bacteriophage SP6 RNAP. Screening was performed using 96-well microplates. Reactions contained (50 mL): 5 mL extract (dissolved in 10% DMSO), 0.2 U E. coli RNAP s 70 holoenzyme (Sigma-Aldrich) or 0.2 U SP6 RNAP (Promega), 0.2 nM plasmid pUC18 (Clontech/Takara; for assays with E. coli RNAP) or 0.2 nM plasmid pGEM-3Z (Promega; for assays with SP6 RNAP), 500 mM ATP, 500 mM GTP, 500 mM CTP, and 2 mM [a 32 P]UTP (0.2 Bq/fmol; PerkinElmer), in 20 mM Tris-acetate (pH 7.9), 50 mM KCl, 4 mM magnesium acetate, 0.1 mM EDTA, 5 mM dithiothreitol, and 100 mg/mL bovine serum albumin. Reaction components except DNA were pre-equilibrated 10 min at 22 C. Reactions were initiated by addition of DNA, were allowed to proceed 1 hr at 22 C, and were terminated by addition of 150 mL ice-cold 10% (w/v) trichloroacetic acid (TCA). After 1 hr at 4 C, resulting TCA precipitates were collected on glass-fiber filters (UniFilter GF/B; PerkinElmer) using a 96-well harvester (Packard/PerkinElmer) and were washed once with water. Radioactivity was quantified using a TopCount scintillation counter (Packard/PerkinElmer), and % inhibition was calculated as:
where R sample , R pos and R neg are observed radioactivity levels in a reaction, in a control reaction without extract, and in a control reaction without plasmid, respectively. Two extracts that inhibited the reaction with E. coli RNAP by R 80%, that did not inhibit the reaction with SP6 RNAP, and that did not contain mass-spectrometry signals indicative of a previously characterized RNAP inhibitor, were designated as ''hit extracts.''
Characterization of producer strains
The producer strains of the hit extracts were strains ID38640 and ID38673. ID38640 and ID38673 are Actinobacterial isolates from soil samples collected in Italy and France, respectively. ID38640 and ID38673 exhibit cell morphologies consistent with the genus Streptomyces and exhibit 16S rRNA gene sequences (determined as in Mazza et al., 2003 ; GenBank accession numbers GI: JQ929050 and GI: JQ929051) that were 99.9% identical over 1.4 kB to each other and were highly similar to those of a cluster of closely-related Streptomyces species (S. nigrescens, S. tubercidicus, S. rimosus subsp. rimosus, S. hygroscopicus subsp. angustmyceticus, and S. libani subsp. libani).
Isolation and purification of pseudouridimycin
For each producer strain of a hit extract, the strain was cultured on a 55 mm BTT agar (Donadio et al., 2009) plate for 4-7 days at 30 C, the mycelium was scraped from the plate and used to inoculate a 50 mL Erlenmeyer flask containing 15 mL of seed medium (20 g/L dextrose monohydrate, 2 g/L yeast extract, 8 g/L soybean meal, 1 g/L NaCl, and 4 g/L CaCO 3 , pH 7.3), and the resulting culture was incubated 48 hr at 30 C on a rotary shaker (200 rpm agitation). Following initial incubation, 5 mL of the culture was used to inoculate 100 mL of fresh seed medium in a 500 mL flask, and the resulting culture was incubated 72 hr under the same conditions. A 5% (v/v) inoculum was transferred into 2 L of production medium (10 g/L dextrose monohydrate, 24 g/L maize dextrin, 8 g/L soy peptone, 5 g/L yeast extract, and 1 g/L NaCl, pH 7.2) in a 3-L vessel, and the resulting culture was grown in a BioFlo 115 Fermentor (Eppendorf) 96 hr at 30 C, with aeration at 0.5 volume air per volume medium per min and stirring at 600 rpm. The culture was filtered through 10.25 00 disc filter paper (Scienceware/Bel-Art), and the resulting cleared broth was concentrated to $1 L in vacuo and loaded onto a column of 500 mg of Dowex 50W x 400 mesh (previously activated with two bed volumes of 5% HCl and washed with H 2 O until neutralization). After washing with 5 bed volumes each of 20 mM sodium acetate at pH 6 and sodium acetate at pH 7, PUM was eluted using six bed volumes of 100 mM NH 4 OAc at pH 9. PUM-containing fractions were desalted by reversed-phase medium-pressure liquid chromatography on Combiflash Rf (Teledyne Isco) using a 30 g C18 RediSep Rf column (Teledyne Isco) with linear gradient from 0 to 20% phase B in 20 min (phase A, 0.02% trifluoroacetic acid in H 2 O; phase B, acetonitrile) and flow rate of 35 mL/min. PUM-containing fractions were pooled, concentrated, and lyophilized twice to yield 196 mg of a white solid highly soluble in water, DMSO, and methanol.
Structure elucidation of PUM Ion-trap ESI-MS (Bruker Esquire 3000 Plus) showed a protonated molecular ion at m/z 487 [M+H] + and a bimolecular ion at 973
[2M+H] + ( Figure S1A ). Reversed-phase HPLC (Shimadzu Series 10 with SPD-M10Avp diode array detector; Waters Symmetry Shield RP8 5 mm, 250 3 4.6 mm, column; phase A = 2 mM heptafluorobutyric acid in water; phase B = 2 mM heptafluorobutyric acid in acetonitrile; gradient = 0% B at 0 min, 10% B at 20 min, 95% B at 30 min; flow rate = 1 mL/min) showed a single peak with a retention time of 12 min. The UV-absorbance spectrum showed maxima at 200 nm and 262 nm, consistent with the presence of a pyrimidine moiety (Ploeser and Loring, 1949; Figure S1A ).
The 1 H NMR spectrum (600 and 400 MHz Bruker spectrometer in DMSO-d6 at 25 C) revealed one olefinic (H6), five amide (H6 0 , H3, H5, Ha, and Hε-Gln), four methylene (Hb-Gln, Hg-Gln, Ha-Gly, and H5 0 ), and five methine (H1 0 , H2 0 , H3 0 , H4 0 , and Ha-Gln) signals ( Figure S1B) . The 2D 1 H-13 C-HSQC and -HMBC NMR spectra (600 and 400 MHz Bruker spectrometer in DMSO-d6 at 25 C) identified five carboxyl-amide groups (C2, C4, C = O Gln, C = O Gly, and Cd-Gln), two olefinic carbons (C1 and C6), four methine carbons belonging to a sugar ring (C1 0 , C2 0 , C3 0 , and C4 0 ), one other methine carbon (Ca-Gln), and four methylene groups (Ca-Gly, Cb-Gln, Cg-Gln, and C5 0 ) ( Figures S1C and S1D 0 to C1, C2 and C6, and HMBC correlations of H6 to C1 0 , C1, C2, and C6, indicated the presence of uracil C-linked to C1 0 of 6 0 -amino-ribose.
13
C-NMR spectra and COSY indicated the presence of a glutaminyl moiety, and HMBC correlations of H6 0 and the methine at d H 4.72 (Ha-Gln) to the carbonyl at d c 169.5 indicated linkage of the glutaminyl moiety to N6 0 of 6 0 -amino-ribose. Nε at d 108.9 was assigned by N-HSQC. The absence of a glutaminyl Na signal in the N-HSQC spectrum suggested the possible presence of an hydroxamic acid, and this was confirmed by reduction of PUM with aqueous TiCl 3 (Mattingly and Miller, 1980) to yield desoxy-PUM (1 in Figure 5A The stereochemistry of the glutamine residue was established to be (L) by total hydrolysis followed by chiral GC-MS (HewlettPackard HP5985B GC-MS; procedures as in Kettenring et al., 1991) . The stereochemistry of the ribose sugar was inferred to be D by analogy to the natural product pseudouridine and was confirmed to be D by comparison of a sample of desoxy-PUM prepared by reduction of PUM with TiCl 3 to a sample of desoxy-PUM prepared by total synthesis using a D-ribose precursor (Figures 5A and 5B).
Effects of PUM on macromolecular synthesis
Cultures of Staphylococcus simulans strain M22 in 0.5x Mueller Hinton II broth (BD Biosciences) were incubated at 37 C with shaking until OD 600 = 0.5; diluted in the same medium to OD 600 = 0.1-0.2; supplemented with 6 kBq/mL [2-
14 C]-thymidine (Hartmann Analytic), 40 kBq/mL [5-3 H]-uridine (Hartmann Analytic), or 6 kBq/mL L-[ 14 C(U)]-isoleucine (Hartmann Analytic); and further incubated at 37 C with shaking. After 15 min, cultures were divided into two equal aliquots, PUM was added to one aliquot to a final concentration of 100-200 mM, and cultures were further incubated at 37 C with shaking. At time points 0, 10, 20, and 40 min following addition of PUM, 200 mL aliquots were removed, mixed with 2 mL ice-cold 10% TCA containing 1 M NaCl, and incubated 30-60 min on ice. The resulting TCA precipitates were collected by filtration on glass-microfiber filters (GF/C; Whatman/GE Healthcare), and filters were washed with 5 mL 2.5% TCA containing 1 M NaCl, transferred to scintillation vials, and dried. Filtersafe scintillation fluid was added (2 mL; Zinnser Analytic), and radioactivity was quantified by scintillation counting (Tri-Carb 3110TR Liquid Scintillation Analyzer; PerkinElmer).
RNAP-inhibitory activity in vitro
For experiments in Figure 1B and Table S1 Table S1 ), in 10 mM Tris-HCl (pH. 7.8), 2 mM HEPES-NaOH, 40 mM KCl, 3 mM MgCl 2 , 0.2 mM dithiothreitol, 0.09 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, and 10% glycerol. Reaction components except RNAP were pre-equilibrated 10 min at 30 C. Reactions were initiated by addition of RNAP, were allowed to proceed 15 min at 30 C, and were terminated by addition of 175 mL HeLa Extract Stop Solution (Promega). Samples were phenol extracted and ethanol precipitated (procedures as in Sambrook and Russell, 2001) , and pellets were resuspended in 10 mL 47.5% formamide, 10 mM EDTA, 0.025% bromophenol blue, and 0.01% xylene cyanol and heated 5 min at 95 C. Products were applied to denaturing 6% polyacrylamide (19:1 acrylamide:bisacrylamide; 7 M urea) slab gels (Sambrook and Russell, 2001) , and gels were electrophoresed in TBE (Sambrook and Russell, 2001 ) at 10 V/cm for 1.5 hr, dried using a gel dryer (Bio-Rad), and analyzed by storage-phosphor imaging (Typhoon; GE Healthcare).
For experiments in Figure 1B and Table S1 assessing promoter-dependent transcription by human RNAP I, human RNAP II, and human RNAP III, reaction mixtures contained (25 mL): 0-80 mM PUM, HeLa nuclear extract [3 mL HeLa nuclear extract prepared as in Schreiber et al., 1989, using $4x10 7 HeLa cells grown to 70%-80% confluence in DMEM, high glucose, 2 mM L-glutamine medium containing 10% fetal bovine serum (GIBCO/ThermoFisher) and 1% penicillin-streptomycin (GIBCO/ThermoFisher) for assays of human RNAP I; or 6 U HeLaScribe Nuclear Extract (Promega) for assays of human RNAP II and human RNAP III], promoter DNA [4 nM EcoRI-linearized plasmid pHrP2x (Pfleiderer et al., 1990) carrying human rDNA promoter for assays of human RNAP I (yields 379 nt transcript); 20 nM HeLaScribe Positive Control DNA (Promega) carrying cytomegalovirus immediate early promoter for assays of human RNAP II (yields 363 nt transcript with same sequence as E.-coli-RNAP-dependent transcript of preceding paragraph); or 2 nM plasmid pVAI (Dean and Berk, 1988) carrying adenovirus VAI promoter for assays of human RNAP III (yields 160 nt transcript)], 20 mM [a 32 P]GTP (0.3 Bq/fmol: PerkinElmer), 400 mM ATP, 400 mM CTP, and 6.25, 50, or 250 mM UTP, in transcription buffer [12 mM HEPESNaOH (pH 7.9), 75 mM KCl, 5 mM MgCl 2 , 10 mM creatine phosphate, 0.5 mM dithiothreitol, 0.1 mM EDTA, and 12% glycerol, for assays with human RNAP I; 10 mM Tris-HCl (pH 7.8), 2 mM HEPES-NaOH, 44 mM KCl, 3 mM MgCl 2 , 0.2 mM dithiothreitol, 0.09 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, and 10% glycerol, for assays with human RNAP II and human RNAP III]. Procedures were as in the preceding paragraph.
For experiments in Figure 1B assessing Table S1 ), in 40 mM Tris-HCl (pH 7.9), 6 mM MgCl 2 , 2 mM spermidine, 10 mM NaCl, 10 mM dithiothreitol, and 10 mg/mL bovine serum albumin. Reaction components except DNA were pre-equilibrated 15 min at 37 C. Reactions were initiated by addition of DNA, were allowed to proceed 15 min at 37 C, and were terminated by addition of 150 mL ice-cold 10% (w/v) TCA. After 30 min on ice, the resulting TCA precipitates were collected on glass-fiber filters (UniFilter GF/C; PerkinElmer) using a 96-well harvester (Packard/PerkinElmer). filters were washed once with water, and radioactivity was quantified using a TopCount scintillation counter (Packard/PerkinElmer).
For experiments in Figure 1B assessing transcription by f6 RNA-dependent RNAP, reaction mixtures contained (20 mL): 0-400 mM PUM, 0.5 U f6 RNAP (Thermo Fisher), 2 mg poly(A) ssRNA (GE Healthcare), 1 mM poly(U-15) ssRNA primer (Sigma-Aldrich), 400 mM ATP, 400 mM GTP, 400 mM CTP, and 1.56 mM [a 32 P]UTP (0.02 Bq/fmol; PerkinElmer) in 50 mM Tris-acetate (pH 8.7), 50 mM ammonium acetate, and 1.5 mM MnCl 2 . Reaction components other than RNA template, RNA primer, and NTPs were pre-incubated 10 min at 30 C. Reactions were initiated by addition of RNA template, RNA primer, and NTPs, reactions were allowed to proceed 1 hr at 30 C, and reactions were terminated by spotting on DE81 filter discs (Whatman; pre-wetted with water) and incubating 1 min at 22 C. Filters were washed with 3x3 mL 0.5 M sodium phosphate dibasic, 2x3 mL water, and 3 mL ethanol using a filter manifold (Hoefer); filters were placed in scintillation vials containing 10 mL Scintiverse BD Cocktail (ThermoFisher); and radioactivity was quantified by scintillation counting (LS6500; Beckman-Coulter). For experiments in Table S1 assessing promoter-independent transcription by E. coli RNAP and HeLa nuclear extract (human RNAP I/II/II), reaction mixtures contained (20 mL): 0-100 mM PUM, 100 nM E. coli RNAP core enzyme or 8 U HeLaScribe Nuclear Extract (Promega), 1 mg human placental DNA (Sigma-Aldrich; catalog number D7011), 400 mM ATP, 400 mM GTP, and 400 mM CTP, and 1.56, 25, or 400 mM [a 32 P]UTP (0.1-1 Bq/fmol; PerkinElmer), in 40 mM Tris-HCl (pH 8.0), 7 mM HEPES-NaOH, 70 mM ammonium sulfate, 30 mM KCl, 12 mM MgCl 2 , 5 mM dithiothreitol, 0.1 mM EDTA, and 12% glycerol. Procedures were as in Degen et al., 2014 . Reaction components other than DNA and NTPs were pre-incubated 10 min at 30 C, DNA was added, and reaction components other than NTPs were incubated 15 min at 30 C. Reactions were initiated by addition of NTPs, reactions were allowed to proceed 1 hr at 30 C, and reactions were terminated by spotting on DE81 filter discs (Whatman; pre-wetted with water) and incubating 1 min at 22 C. Filters were washed, and radioactivity on filters was quantified, as in the preceding paragraph. For experiments in Figures S3C and 5C , fluorescence-detected transcription assays were performed as in Zhang et al., 2014. Half-maximal inhibitory concentrations (IC 50 s) were calculated by non-linear regression in SigmaPlot (Systat Software).
Antibacterial activity in vitro
Antibacterial activities in vitro ( Figure 1C , rows 1-20; Figure 5D ) were determined using broth-microdilution growth-curve assays (Holowachuk et al., 2003) . [PUM degrades in phosphate-containing media with a half-life of $12 hr. Broth-microdilution endpoint assays (CLSI/NCCLS, 2009), which have a run time of 16-24 hr (CLSI/NCCLS, 2009), which corresponds to 1.3 to 2 PUM half-lives, underestimate absolute antibacterial activities of PUM. Broth-microdilution growth-curve assays (Holowachuk et al., 2003) , which have shorter run times between assay start and assay signal, more accurately estimate absolute antibacterial activities of PUM.] Colonies of the indicated bacterial strains (5 to 10 per strain) were suspended in 3 mL phosphate-buffered saline (Sambrook and Russell, 2001) , suspensions were diluted to 1x10 5 cfu/mL with growth medium [Todd Hewitt broth (BD Biosciences) for S. pyogenes and S. pneumoniae, aged Mueller Hinton II cation-adjusted broth (BD Biosciences; autoclaved and allowed to stand 2-12 months at room temperature before use) for Staphylococcus aureus and Enterococcus faecium, fresh Mueller Hinton II cation-adjusted broth (autoclaved and used immediately) for Moraxella catarrhalis, or fresh Mueller Hinton II cation-adjusted broth (BD Biosciences; autoclaved and used immediately) containing 0.4% Haemophilus Test Medium (Barry et al., 1993) and 0.5% yeast extract for Haemophilus influenzae], 50 mL aliquots were dispensed into wells of a 96-well microplate containing 50 mL of the same medium or 50 mL of a 2-fold dilution series of PUM in the same medium (final concentrations = 0 and 0.25-256 mM), plates were incubated at 37 C with shaking, and optical densities at 600 nm were recorded at least hourly using a Synergy 2 (BioTek) or GENios Pro (Tecan) microplate reader. For each dilution series, growth curves were plotted, areas under growth curves were calculated, and IC 50 was extracted as the lowest tested concentration of PUM that reduced area under the growth curve to 50% that in the absence of PUM (using only time points for rise phase of the growth curve in the absence of PUM).
Identical results were obtained in assays in the absence and presence of 30% human serum (Sigma-Aldrich; Figure 1C , rows 1-4), indicating that PUM does not bind tightly to human serum proteins (unbound fraction $100%).
Cytotoxicities for human macrovascular endothelial cells and human monocytes in culture ( Figure 1C , rows 21-22) were determined as in Mazzetti et al., 2012. Antibacterial activity in vivo Antibacterial activity in vivo was assessed in a mouse S. pyogenes peritonitis model ( Figure 1D ; Table S2 ). Female ICR mice (weight = 23-25 g; Harlan Laboratories Italy) were adapted to standardized environmental conditions (temperature = 23±2 C; humidity = 55±10%) for one week prior to infection. Infection was induced by intraperitoneal injection of 0.5 mL saline solution (supplemented with 1% peptone) containing 4 3 10 3 cfu S. pyogenes C203 (an inoculum resulting in R 95% mortality in untreated controls within 48 to 72 hr after infection). Infected mice (eight mice per group; number determined by power calculations; assigned randomly to groups; unblinded) were treated with either: (i) 0.2 mL 5% dextrose or 0.2 mL of a 2.5-fold dilution series of PUM in 5% dextrose, administered intravenously 10 min after infection and again 6 hr after infection (total PUM dose = 0 or 3.2-50 mg/kg), (ii) 0.25 mL 5% dextrose or 0.25 mL of a 2.5-fold dilution series of PUM in 5% dextrose, administered intravenously 10 min after infection (total PUM dose = 0 or 1.024-40 mg/kg), or (iii) 0.25 mL 5% dextrose or 0.25 mL of a 2.5-fold dilution series of PUM in 5% dextrose, administered subcutaneously 10 min after infection (total PUM dose = 0 or 1.024-40 mg/kg). Survival was monitored for 7 days after infection. Experiments were performed in compliance with vertebrate animal ethical regulations and with Institutional Animal Care and Use Committee (IACUC) approval. ED 50 s (doses yielding 50% survival at 7 days) and 95% confidence limits were calculated using the trimmed Spearman-Karber method as implemented in the US EPA LC50 Model System (Hamilton et al., 1977 ; http://sdi.odu.edu/model/lc50.php).
Checkerboard interaction assays
Antibacterial activities of combinations of PUM and Rif were assessed in checkerboard interaction assays (White et al., 1996; Meletiadis et al., 2010;  Figure 1E ). Broth-macrodilution assays (procedures as in CLSI/NCCLS, 2009) were performed in checkerboard format, using S. pyogenes strain L49 or S. pneumoniae strain L44, and using Todd Hewitt broth (BD Biosciences) containing pairwise combinations of: (i) PUM at 1x, 0.5x, 0.25x, 0.125x, 0.063x, 0.031x, 0.016x, and 0.0078x MIC PUM and (ii) Rif at 0.8x, 0.4x, 0.2x, 0.1x, 0.05x, 0.025x, and 0.0125x MIC Rif . Fractional inhibitory concentrations (FICs), FIC indices (FICIs), and minimum and maximum FICIs (FICI min and FICI max ) were calculated as in Meletiadis et al., 2010 . FICI min % 0.5 was deemed indicative of super-additivity (synergism), FICI min > 0.5 and FICI max % 4.0 was deemed indicative of additivity, and FICI max > 4.0 was deemed indicative of sub-additivity (antagonism) (White et al., 1996; Meletiadis et al., 2010) .
Spontaneous resistance rate assays Spontaneous resistance rates were determined in Luria-Delbrü ck fluctuation assays (Figure 2A ; procedures as in Srivastava et al., 2012) . S. pyogenes strain ATCC 12344 ($1 3 10 9 cfu/plate) was plated on Todd Hewitt agar [Todd Hewitt broth (BD Biosciences) supplemented with 1.5% Bacto agar (BD Biosciences)] containing 64 mg/mL or 128 mg/mL PUM (8x or 16x MIC under these conditions) or 1 mg/mL or 2 mg/mL Rif (8x or 16x MIC under these conditions), and numbers of colonies were counted after 24 hr at 37 C (at least six independent determinations each). Resistance rates and 95% confidence intervals were calculated using the Ma-Sandri-Sarkar Maximum Likelihood Estimator (Ma et al., 1992; Sarkar et al., 1992) as implemented on the Fluctuation Analysis Calculator (Hall et al., 2009 ; http://www.keshavsingh.org/protocols/FALCOR.html).
Spontaneous PUM-resistant mutants, S. pyogenes To isolate spontaneous PUM-resistant mutants of S. pyogenes ( Figure 2B ), a single colony of S. pyogenes ATCC 12344 was inoculated into 5 mL Todd Hewitt broth (BD Biosciences) and incubated 3 hr at 37 C with shaking in a 7% CO 2 /6% O 2 /4% H 2 /83% N 2 atmosphere (atmosphere controlled using Anoxomat AN2CTS; Advanced Instruments), the culture was centrifuged, and the cell pellet ($1 3 10 9 cells) was re-suspended in 50 mL Todd Hewitt broth and plated on Todd Hewitt agar (BD Biosciences) containing 16-256 mg/mL PUM (2-32x MIC under these conditions), and plates were incubated 120 hr at 37 C in a 7% CO 2 /6% O 2 /4% H 2 /83% N 2 atmosphere. PUM-resistant mutants were identified by the ability to form colonies on these media, were confirmed to be PUM-resistant by re-streaking on the same media, and were confirmed to be S. pyogenes (as opposed to contaminants) using Taxo A differentiation discs (BD Biosciences) and Pyrase strips (Fluka/Sigma-Aldrich).
Genomic DNA was isolated using the Wizard Genomic DNA Purification Kit [Promega; procedures as specified by the manufacturer, but with cells lysed using 1 mg/mL lysozyme (Sigma-Aldrich)] and was quantified by measurement of UV-absorbance (procedures as in Sambrook and Russell, 2001 ). The rpoC gene and the rpoB gene were PCR-amplified in reactions containing 0.2 mg genomic DNA, 0.4 mM forward and reverse oligodeoxyribonucleotide primers (5 0 -GGGCAAATGATAACTTAGTTGCGATTTGCTG-3 0 and 5 0 -CCTTTCTGCCTTTGATGACTTTACCAGTTC-3 0 for rpoB; 5 0 -GCTCAAGAAACTCAAGAAGTTTCTGAAACAACTGAC-3 0 and 5 0 -GTCAATGCTTTTTACTGCCAACAAACTCAGAC-3 0 for rpoC), 5 U Taq DNA polymerase (Genscript), and 800 mM dNTP mix (200 mM each dNTP; Agilent/Stratagene) (initial denaturation step of 3 min at 94 C; 30 cycles of 30 s at 94 C, 45 s at 53 C, and 4 min at 68 C; final extension step of 10 min at 68 C). PCR products containing the rpoC gene (3.6 kB) or the rpoB gene (3.6 kB) were isolated by electrophoresis on 0.8% agarose gels (procedures as in Sambrook and Russell, 2001) , extracted from gel slices using a Gel/PCR DNA Fragments Extraction Kit (IBI Scientific; procedures as specified by the manufacturer), and sequenced (GENEWIZ; Sanger sequencing; seven sequencing primers per gene).
Spontaneous PUM-resistant mutants, E. coli To isolate spontaneous PUM-resistant mutants of E. coli ( Figure S3A ), E. coli uptake-proficient, efflux-deficient strain D21f2tolC (Fralick and Burns-Keliher, 1994 ) was cultured to saturation in 10 mL LB broth (Sambrook and Russell, 2001) at 37 C, cultures were centrifuged, cell pellets ($1 3 10 10 cells) were re-suspended in 50 mL LB broth and plated on LB agar (Sambrook and Russell, 2001 ) containing 800 mg/mL PUM ($1x MIC under these conditions), and plates were incubated 96-120 hr at 37 C. PUM-resistant mutants were identified by the ability to form colonies on this medium.
Genomic DNA was isolated, and rpoB and rpoC genes were PCR-amplified and sequenced, as in Degen et al., 2014. Resistance and cross-resistance levels Resistance levels of S. pyogenes and E. coli spontaneous PUM-resistant mutants (Figures 2B and S3B) were quantified in broth-microdilution assays. A single colony of a mutant strain or the isogenic wild-type parent strain was inoculated into 5 mL Todd Hewitt broth (BD Biosciences; for S. pyogenes) or LB broth (Sambrook and Russell, 2001 ; for E. coli) and incubated at 37 C with shaking in a 7% CO 2 /6% O 2 /4% H 2 /83% N 2 atmosphere (atmosphere controlled using Anoxomat AN2CTS; Advanced Instruments); for S. pyogenes) or in air (for E. coli) until OD 600 = 0.4-0.8. Diluted aliquots ($2 3 10 5 cells in 50 mL same medium) were dispensed into wells of a 96-well microplate containing 50 mL of the same medium or 50 mL of a 2-fold dilution series of PUM in the same medium (final PUM concentration = 0 or 0.098-800 mg/mL), and were incubated 16 hr at 37 C with shaking in a 7% CO 2 /6% O 2 /4% H 2 /83% N 2 atmosphere (for S. pyogenes) or in air (for E. coli). MIC was defined as the lowest tested concentration of PUM that inhibited bacterial growth by R 90%. MIC/MIC wild-type was defined as the ratio of MIC for mutant to MIC for isogenic wild-type parent (S. pyogenes MIC wild-type = 6.25 mg/mL under these conditions; E. coli MIC wild-type = 400 mg/mL under these conditions).
Cross-resistance levels of S. pyogenes and E. coli spontaneous PUM-resistant mutants (Figures 2E and S3F) were determined as in the preceding paragraph, but using culture aliquots ($1x10 5 cells) in 97 mL growth medium supplemented with 3 mL methanol or 049 mg/mL) in methanol (final concentrations = 0 and 0.006-50 mg/mL), or using culture aliquots ($2x10 5 cells) in 50 mL growth medium supplemented with 50 mL growth medium or 50 mL of a 2-fold dilution series of GE23077 (GE; prepared as in Ciciliato et al., 2004 ; E. coli MIC wild-type = 500 mg/mL) in growth medium (final concentrations = 0 and 125-8000 mg/mL).
Cross-resistance levels of S. pyogenes Rif-resistant mutants to PUM ( Figure 1E ) were determined as described for cross-resistance levels of S. pyogenes spontaneous PUM-resistant mutants, but analyzing a collection of 13 S. pyogenes spontaneous Rifresistant mutants [isolated and sequenced using the same procedures used for isolation and sequencing of S. pyogenes PUM-resistant mutants (Methods, Spontaneous PUM-resistant mutants, S. pyogenes), but using Todd Hewitt agar containing 1-16x MIC Rif (0.1-2 mg/mL under these conditions)] and the isogenic wild-type parent, and analyzing a 2-fold dilution series of PUM (final concentration = 0 or 1.56-100 mg/mL).
Cross-resistance levels of E. coli Rif-, Lpm-, Myx-, and Sal-resistant mutants to PUM ( Figures S3G-S3I and S3L) were determined as described for resistance levels of E. coli spontaneous PUM-resistant mutants, but analyzing a collection of E. coli D21f2tolC derivatives comprising four chromosomal Rif-resistant mutants, five chromosomal Lpm-resistant mutants, five chromosomal Myx-resistant mutants, five chromosomal Sal-resistant mutants, and the isogenic wild-type parent (Degen et al., 2014) , and analyzing a 2-fold dilution series of PUM (final concentration = 0 or 25-1600 mg/mL).
Cross-resistance levels of E. coli Stl-, CBR-, and GE-resistant mutants to PUM ( Figures S3J, S3K , and S3N) were determined analogously, analyzing a collection of E. coli D21f2tolC pRL706 and E. coli D21f2tolC pRL663 derivatives comprising five plasmid-based Stl-resistant mutants, five plasmid-based CBR-resistant mutants, six plasmid-based GE-resistant mutants, and plasmid-based wildtype isogenic parents (Tuske et al., 2005; Zhang et al., 2014; Feng et al., 2015) . Single colonies were inoculated into 5 mL LB broth containing 200 mg/mL ampicillin (Sigma-Aldrich), incubated at 37 C with shaking until OD 600 = 0.4-0.8, supplemented with IPTG (Gold Bio) to a final concentration of 1 mM, and further incubated 1 hr at 37 C with shaking. Diluted aliquots ($2 3 10 5 cells in 50 mL LB broth containing 200 mg/mL ampicillin and 1 mM IPTG) were dispensed into wells of a 96-well microplate containing 50 mL of the same medium or 50 mL of a 2-fold dilution series of PUM in the same medium (final concentration = 0 or 25-4000 mg/mL), and were incubated 16 hr at 37 C with shaking. Amino-acid substitutions that confer PUM-resistance in the context of S. pyogenes RNAP were re-constructed and re-analyzed in the context of E. coli RNAP using an E. coli plasmid-based resistance assay ( Figure S3B ). Site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Agilent) was used to construct plasmid pRL706 (Severinov et al., 1997) and pRL663 (Wang et al., 1995) derivatives encoding E. coli RNAP b-subunit and b'-subunit derivatives having amino-acid substitutions that confer PUMresistance in S. pyogenes (sequences from Figure 2B ). The resulting plasmids were introduced by transformation into E. coli strain D21f2tolC (Fralick and Burns-Keliher, 1994) , and resistance levels of transformants were determined using the procedures of the preceding paragraph.
Formation of RNAP-promoter open complex
Experiments ( Figure S4A ) were performed as in Mukhopadhyay et al., 2008 . Reaction mixtures contained (20 mL): test compound (0 or 500 mM PUM, 2 mM Rif, or 100 mM Lpm), 40 nM E. coli RNAP s 70 holoenzyme, 10 nM Cy5-labeled DNA fragment carrying positions À40 to +15 of lacUV5 promoter (lacUV5- [-40 ;+15]-Cy5; Mukhopadhyay et al., 2008) , and 100 mg/mL heparin, in 50 mM Tris-HCl (pH 8.0), 100 mM KCl, 10 mM MgCl 2 , 1 mM dithiothreitol, 10 mg/mL bovine serum albumin, and 5% glycerol. Reaction components other than DNA and heparin were incubated 10 min at 37 C; DNA was added and reactions were incubated 15 min at 37 C; and heparin was added and reactions were incubated 2 min at 37 C. Products were applied to 5% TBE-polyacrylamide slab gels (Bio-Rad), electrophoresed in TBE (Sambrook and Russell, 2001) , and analyzed by fluorescence scanning (Typhoon 9400; GE Healthcare).
Nucleotide addition in transcription initiation
Experiments were performed as in Zhang et al., 2014, using reaction mixtures that contained no inhibitor, 500 mM PUM, 2 mM Rif, or 100 mM Lpm, and using 5 mM [a 32 P]UTP (3 Bq/fmol; PerkinElmer) ( Figure S4B ).
Nucleotide addition in transcription elongation
Experiments were performed as in Zhang et al., 2014, using reaction mixtures that contained no inhibitor, 500 mM PUM, 2 mM Rif, or 100 mM Lpm ( Figure S4C ).
Nucleotide addition at elevated NTP concentrations Experiments ( Figure 3A ) were performed as described above for assays of promoter-dependent transcription by B. subtilis RNAP (Methods, RNAP-inhibitory activity in vitro), using reaction mixtures (50 mL) that contained 0 or 6 mM PUM, 0.4 U E. coli RNAP s 70 holoenzyme (Epicentre), 0.4 nM plasmid pUC19 (Clontech/Takara), 80 mM HEPES-KOH (pH 7.6), 80 mM KCl, 4 mM MgCl 2 , 0.1 mM EDTA, 5 mM dithiothreitol, 100 mg/mL bovine serum albumin, and either (i) 100 mM ATP, 100 mM [a 32 P]CTP (0.2 Bq/fmol; PerkinElmer), 100 mM GTP, and 10-500 mM UTP; (ii) 10-500 mM GTP, 100 mM ATP, 100 mM CTP, and 2 mM [a 32 P]UTP (0.2 Bq/ fmol; PerkinElmer); (iii) 100 mM GTP, 10-500 mM ATP, 100 mM CTP, and 2 mM [a C. Relative nucleotide incorporation was defined as the ratio of nucleotide incorporation in the presence of PUM to nucleotide incorporation in the absence of PUM.
Nucleotide addition on standard and ''U-less cassette'' templates Experiments ( Figure 3B ) were performed as described in the preceding section (Methods, Nucleotide addition at elevated NTP concentrations), using reaction mixtures (50 mL) that contained 0-20 mM PUM, 0.4 U E. coli RNAP s 70 holoenzyme (Epicentre), 2 mM [a 32 P] CTP (0.2 Bq/fmol; PerkinElmer), 100 mM ATP, 100 mM GTP, and 5 mM UTP, in 40 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 5 mM dithiothreitol, 15 mM KCl, 0.01% Triton X-100, and 100 mg/mL bovine serum albumin, and either (i) 50 nM DNA fragment carrying positions À112 to +8 of the E. coli recA promoter (Sancar et al., 1980) followed by 5 0 -CAGGGACAAGTTAGTTCGTTCAGCGACACGCGGCAA CAAG-3 0 (directs incorporation of U, G, A, and C) or (ii) 50 nM DNA fragment carrying positions À112 to +8 of the E. coli recA promoter followed by 5 0 -CAGGGACAAGGAGACCAACGCAGCGACACGCGGCAACAAG-3 0 (''U-less cassette''; directs incorporation of G, A, and C). The reaction time was 60 min at 37 C. Relative nucleotide incorporation was defined as the ratio of nucleotide incorporation in the presence of PUM to nucleotide incorporation in the absence of PUM.
Template-sequence specificity of inhibition by PUM: single-nucleotide-addition reactions Template-sequence specificity of inhibition by PUM was assessed in single-nucleotide-addition experiments ( Figure 3C ) using E. coli RNAP transcription elongation complexes assembled on the nucleic-acid scaffolds in Table S5 .
Nucleic-acid scaffolds for single-nucleotide-addition reactions were prepared as follows: 1 mM nontemplate-strand oligodeoxyr- , 200 mM NaCl, and 10 mM MgCl 2 , were heated 5 min at 95 C, cooled to 4 C in 2 C steps with 1 min/step using a thermal cycler (Applied Biosystems), and stored at À20 C. Reaction mixtures for single-nucleotide-addition reactions contained (10 mL): 0 or 25 mM PUM, 40 nM E. coli RNAP core enzyme, 10 nM nucleic-acid scaffold, and 2.5 mM ATP, GTP, CTP, or UTP, in 50 mM Tris-HCl (pH 8.0), 100 mM KCl, 10 mM MgCl 2 , 1 mM dithiothreitol, 10 mg/mL BSA, and 5% glycerol. Reaction components except PUM and NTP were pre-incubated 10 min at 37 C, PUM was added and reaction mixtures were incubated 5 min at 37 C, and NTP was added and reaction mixtures were incubated 5 min at 37 C. Reactions were terminated by addition of 5 mL 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, 0.04% xylene cyanol, and 0.08% amaranth red, and heating 2 min at 95 C. Samples were applied to denaturing 15% polyacrylamide (19:1 acrylamide:bisacrylamide; 7 M urea) slab gels (Sambrook and Russell, 2001) , electrophoresed in TBE (Sambrook and Russell, 2001) , and analyzed by storage-phosphor scanning (Typhoon 9400; GE Healthcare).
Template-sequence specificity of inhibition by PUM: multiple-nucleotide-addition reactions Template-sequence specificity of inhibition by PUM was assessed in multiple-nucleotide-addition experiments ( Figure 3D ), performed by adding PUM to transcription elongation complexes halted at position +29 of a 100 bp transcription unit by omission of CTP, re-starting transcription elongation complexes and allowing transcription of positions +30 to +100 of the transcription unit by addition of CTP, and identifying positions at which PUM inhibits transcription.
Halted transcription elongation complexes were prepared as in Revyakin et al., 2006 . Reaction mixtures (20 mL) contained: 40 nM E. coli RNAP s 70 holoenzyme, 10 nM DNA fragment N25-100-tR2 (Revyakin et al., 2006) , 100 mg/mL heparin, 5 mM [g 32 P]ATP (6 Bq/fmol; PerkinElmer), 5 mM UTP, and 5 mM GTP, in 50 mM Tris-HCl (pH 8.0), 100 mM KCl, 10 mM MgCl 2 , 1 mM dithiothreitol, 10 mg/mL bovine serum albumin, and 5% glycerol. Reaction components other than heparin and NTPs were pre-incubated 5 min at 30 C; heparin was added and reaction mixtures were incubated 2 min at 30 C; NTPs were added and reaction mixtures were incubated 3 min at 30 C. Halted transcription elongation complexes were provided with PUM (1.25 mL 125 mM PUM, 1.25 mL 250 mM PUM, 1.25 mL 500 mM PUM, or 1.25 mL 1 mM PUM) or, to provide markers, chain-terminating 3 0 -O-methyl-NTPs (RiboMed; 1.25 mL 400 mM 3 0 -O-methyl-UTP, 1.25 mL 400 mM 3 0 -O-methyl-CTP, 1.25 mL 400 mM 3 0 -O-methyl-GTP, or 1.25 mL 400 mM 3 0 -Omethyl-ATP), were incubated 3 min at 30 C, were re-started by addition of 0.625 mL 200 mM UTP, 1.25 mL 200 mM CTP, 0.625 mL 200 mM GTP, and 0.625 mL 200 mM ATP, and were further incubated 10 min at 30 C. Reactions were terminated by addition of 12.5 mL 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, 0.04% xylene cyanol, and 0.08% amaranth red, and heating 4 min at 95 C. Samples were applied to denaturing 10% polyacrylamide (19:1 acrylamide:bisacrylamide; 7 M urea) slab gels (Sambrook and Russell, 2001) , electrophoresed in TBE (Sambrook and Russell, 2001) , and analyzed by storage-phosphor scanning (Typhoon 9400; GE Healthcare).
Structure determination: RPo-GpA-PUM Crystals of T. thermophilus RPo-GpA were prepared as in Zhang et al., 2012 . Crystallization drops contained 1 mL 18 mM RPo (prepared from T. thermophilus RNAP s A holoenzyme and synthetic nucleic-acid scaffold as in Zhang et al., 2012) and 1 mM GpA (TriLink) in 20 mM Tris-HCl, pH 7.7, 100 mM NaCl, and 1% glycerol, and 1 mL reservoir buffer (RB; 100 mM Tris-HCl, pH 8.4, 200 mM KCl, 50 mM MgCl 2 , and 10% PEG4000), and were equilibrated against 400 mL RB in a vapor-diffusion hanging-drop tray (Hampton Research). Rod-like crystals appeared in 1 day, and grew to a final size of 0.1 mm x 0.1 mm x 0.3 mm in 5 days.
PUM was soaked into RPo-GpA crystals by adding 0.2 mL 100 mM PUM in RB to the crystallization drop and incubating 30 min at 22 C. RPo-GpA-PUM crystals were transferred to reservoir solutions containing 2 mM PUM in 17.5% (v/v) (2R,3R)-(-)-2,3-butanediol (Sigma-Aldrich) and were flash-cooled with liquid nitrogen.
Diffraction data for RPo-GpA-PUM were collected from cryo-cooled crystals at Cornell High Energy Synchrotron Source (CHESS) beamline F1. Data were integrated and scaled using HKL2000 (Otwinowski and Minor, 1997) . Structure factors were converted using the French-Wilson algorithm (French and Wilson, 1978) in Phenix (Adams et al., 2010) and were subjected to anisotropy correction using the UCLA MBI Diffraction Anisotropy server (Strong et al., 2006 ; http://services.mbi.ucla.edu/anisoscale/). The structure of RPo-GpA-PUM was solved by molecular replacement in Molrep (Vagin and Teplyakov, 1997) , using one RNAP molecule from the structure of T. thermophilus RPo (PDB 4G7H; Zhang et al., 2012) as the search model. Early-stage refinement included rigid-body refinement of each RNAP molecule, followed by rigid-body refinement of each subunit of each RNAP molecule. Cycles of iterative model building with Coot (Emsley et al., 2010) and refinement with Phenix (Adams et al., 2010) were performed. Atomic models of the DNA nontemplate strand, the DNA template strand, and GpA were built into the mFo-DFc omit map, and further refinement with Phenix was performed. The atomic model of PUM was built into the mFo-DFc omit map and was refined with Phenix. The final crystallographic model of RPo-GpA-PUM at 3.30 Å resolution, refined to Rwork and Rfree of 0.232 and 0.280, has been deposited in the PDB with accession code PDB: 5X21 ( Figure 4A ; Table S3 ).
Structure determination: RPo-GpA-CMPcPP Crystals of T. thermophilus RPo-GpA-CMPcPP were prepared by co-crystallization. Crystallization drops contained 1 mL 18 mM RPo (prepared from T. thermophilus RNAP s A holoenzyme and synthetic nucleic-acid scaffold as in Zhang et al., 2012), 1 mM GpA (TriLink), and 10 mM CMPcPP (Jena Bioscience) in 20 mM Tris-HCl, pH 7.7, 100 mM NaCl, and 1% glycerol, and 1 mL RB, and were equilibrated against 400 mL RB in a vapor-diffusion hanging-drop tray (Hampton Research). Rod-like crystals appeared in 1 day, and grew to a final size of 0.1 mm x 0.1 mm x 0.3 mm in 5 days. RPo-GpA-CMPcPP crystals were transferred to reservoir solutions containing 2 mM CMPcPP in 17.5% (v/v) (2R,3R)-(-)-2,3-butanediol (Sigma-Aldrich), and were flash-cooled with liquid nitrogen.
Diffraction data for RPo-GpA-CMPcPP were collected from cryo-cooled crystals at CHESS beamline F1. Data were integrated and scaled, structure factors were converted and subjected to anisotropy correction, and the structure was solved and refined using procedures analogous to those in the preceding section. The final crystallographic model of RPo-GpA-CMPcPP at 3.35 Å resolution, refined to Rwork and Rfree of 0.208 and 0.250, has been deposited in the PDB with accession code PDB: 5X22 ( Figure 4B ; Table S3 ).
Semi-synthesis of PUM derivatives
Semi-syntheses of PUM derivatives from PUM corroborate the inferred structure of PUM, provide routes for preparation of novel PUM derivatives, and provide initial structure-activity relationships ( Figures 5A, 5C , and 5D). Reactions were conducted starting from 1 mg PUM, and products were identified by LC-MS (Agilent 1100 with flow split in 1:1 ratio between UV detector and iontrap ESI-MS interface of Bruker Esquire 3000 Plus; Waters Atlantis 3 mm, 50 3 4.6 mm, column; phase A = 0.05% trifluoroacetic acid in water; phase B = acetonitrile; gradient = 5%-95% B in 6 min; flow rate = 1 mL/min; run temperature = 40 C; PUM retention time = 1.4 min).
Reaction Total synthesis of desoxy-PUM Total synthesis of desoxy-PUM provides a reference compound that corroborates the inferred stereochemistry of PUM [by comparison of desoxy-PUM prepared by total synthesis (1 in Figure 5B ) to desoxy-PUM prepared by semi-synthesis from PUM (1 in Figure 5A )] and provides an additional route to novel PUM derivatives. Desoxy-PUM was obtained in eight steps by convergent synthesis from commercially available b-D-pseudouridine and glycyl-L-glutamine, as follows ( Figure 5B) . Acetonide protection Reaction a in Figure 5B . To a solution of b-D-pseudouridine (Berry & Associates; 400 mg, 1.64 mmol) and 2,2-dimethoxypropane (Sigma-Aldrich; 12 mL) in dimethylformamide (8 mL), concentrated HCl (80 mL) was added, and the reaction mixture was stirred 5 hr at room temperature. After neutralization with 2.5 M NaOH, solvent was removed under vacuum. Figure 5B . To a solution of the crude product of the preceding step (419 mg, 1.47 mmol) in pyridine (Sigma-Aldrich; 4.7 mL), methanesulfonyl chloride (Sigma-Aldrich: 95 mL, 1.23 mmol) was added with stirring at 0 C. The reaction mixture was stirred at room temperature until completeness (16 h). Solvent was removed by rotary evaporation, and the raw material was purified by flash chromatography on Combiflash (Teledyne ISCO), yielding 475 mg of a white powder (95% yield Figure 5B . To a solution of the product of the preceding step (475 mg) in dimethylformamide (24 mL), sodium azide (Sigma-Aldrich: 476 mg) was added, the reaction mixture was stirred 4 hr at 100 C, and solvent was removed by rotary evaporation. Figure 5B . To a solution of the crude product of the preceding step (193 mg) in tetrahydrofuran (8.8 mL) and water (1.8 mL), 1 M trimethylphosphine in tetrahydrofuran (Sigma-Aldrich; 0.74 mL) was added, the reaction mixture was stirred 2 hr at room temperature, and solvent was removed by rotary evaporation. Figure 5B . To a solution of the crude product of the preceding step (22 mg, 0.11 mmol) in dioxane (150 mL) and water (250 mL) sodium carbonate (26.5 mg) was added, followed by Fmoc chloride (Sigma-Aldrich; 31 mg, 1.3 eq), and the reaction mixture stirred overnight at room temperature. After addition of water (5 mL), the reaction was extracted with ethyl acetate (3 3 5 mL), the combined organic extracts were extracted with saturated sodium bicarbonate (3 3 5 mL), the combined aqueous extracts were acidified to pH 1 with 1 M HCl and extracted with ethyl acetate (3 3 5 mL), and the combined organic extracts were treated with sodium sulfate and evaporated to dryness, providing Fmoc-glycl-L-glutamine in quantitative yield. Coupling, Fmoc deprotection, and formamidinylation Reactions f-h in Figure 5B . To a solution of the product of the preceding step (20 mg) and the product of the azide-reduction reaction (30 mg, 1.1 eq) in dry dimethylformamide (1.5 mL), N,N 0 -dicyclohexylcarbodiimide (Sigma-Aldrich; 18 mg, 1.2 eq) and 1-hydroxybenzotriazole (Sigma-Aldrich; 19.5 mg, 2 eq) were added, and the reaction mixture was stirred overnight at room temperature, and the solvent was evaporated under reduced pressure. To a solution of the crude coupled product (12 mg) in dimethylformamide (800 mL), piperidine (200 mL) was added, and the reaction mixture was stirred 10 min at 25 C, the solvent was evaporated under reduced pressure, and the residue was washed with methylene chloride (2 3 5 mL). To a solution of the crude Fmoc-deprotected product (22 mg) in methanol (300 mL), 3,5-dimethylpyrazole-1-carboxamidine (Sigma-Aldrich; 45 mg, 10 eq) was added, and the reaction mixture was stirred overnight at room temperature, followed by 6 hr under reflux at 65 C to complete the reaction. The solvent was evaporated under reduced pressure, and the solid residue was washed with methylene chloride (2 3 10 mL). Figure 5B . A solution of the crude product of the preceding step (17 mg) in acetic acid:water (7:3; 2 mL) was stirred overnight at room temperature and then heated to 50 C for 10 hr under argon. The solvent was evaporated under reduced pressure, and the solid residue was washed with methylene chloride (2 3 5 mL) and methanol (2 mL), yielding a white solid that, when analyzed by LC-MS [performed as described for LC-MS of PUM (Methods, Structure Elucidation of PUM); retention time = 14 min], 1D-and 2D-NMR, was indistinguishable from desoxy-PUM obtained by reduction of PUM with TiCl 3 (1 in Figure 5A ). 4, 31.9, 41.4, 44.0, 53.0, 72.3, 73.7, 79.9, 81.6, 110.4, 141.5, 152.2, 158.2, 164.2, 168.0, 171.3, 173.7 .
QUANTITATION AND STATISTICAL ANALYSIS
Data for RNAP-inhibitory activities, growth-inhibitory activities, resistance, and cross-resistance are means of at least two technical replicates. Data for mouse infection models, resistance-rate assays, and checkerboard interaction assays are means and 95% confidence intervals for eight biological replicates, at least six biological replicates, and at least five technical replicates, respectively. 
